BridgeBio Pharma Inc (NASDAQ:BBIO)
| 26.34 Delayed Data As of Sep 29 |  -0.79 / -2.91%Today’s Change | 6.64 Today|||52-Week Range 36.36 | +245.67% Year-to-Date |
Latest BBIO News | Press Releases
| CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants Sep 18 / Zacks.com - Paid Partner Content | Should You Invest in the SPDR S&P Biotech ETF (XBI)? Sep 18 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 27.13 |
| Today’s open | 27.21 |
| Day’s range | 26.07 - 27.29 |
| Volume | 48,671 |
| Average volume (3 months) | 2,737,252 |
| Market cap | $4.4B |
Data as of 4:00pm ET, 09/29/2023
Growth & Valuation
| Earnings growth (last year) | +16.27% |
| Earnings growth (this year) | +2.99% |
| Earnings growth (next 5 years) | -51.17% |
| Revenue growth (last year) | +11.38% |
| P/E ratio | NM |
| Price/Sales | 14.47 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| IDRSFIdorsia Ltd | +0.09 | +3.33% |
| ---- | ||
| IMMBImmunotech Laborator... | 0.00 | 0.00% |
| OASMYVivesto AB | 0.00 | 0.00% |
Data as of 09/29/2023
Financials
| Next reporting date | November 9, 2023 |
| EPS forecast (this quarter) | -$0.77 |
| Annual revenue (last year) | $77.6M |
| Annual profit (last year) | -$481.2M |
| Net profit margin | -619.70% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Palo Alto, California |
Forecasts
